Search Results - "Kish, Jonathan K."

Use of Real-World Evidence to Support FDA Approval of Oncology Drugs by Feinberg, Bruce A., Gajra, Ajeet, Zettler, Marjorie E., Phillips, Todd D., Phillips, Eli G., Kish, Jonathan K.

“…Real-world evidence (RWE) has gained increased attention in recent years as a complement to traditional clinical trials. The use of RWE to establish the…”
Get full text

Earlier presentation and application of curative treatments in hepatocellular carcinoma by Ulahannan, Susanna V., Duffy, Austin G., McNeel, Timothy S., Kish, Jonathan K., Dickie, Lois A., Rahma, Osama E., McGlynn, Katherine A., Greten, Tim F., Altekruse, Sean F.

“…The purpose of the study was to assess the use of curative therapies for hepatocellular carcinoma (HCC) in the population. HCC treatment patterns were examined…”
Get full text

Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA by Kim, Edward S., Kish, Jonathan K., Cseh, Agnieszka, Moehring, Barbara, Tang, Wenbo, Terlizzi, Elizabeth, Subramanian, Janakiraman

“…•Real-world study of afatinib after immunochemotherapy in patients with SqCC of the lung.•Afatinib demonstrated effectiveness and tolerability in this…”
Get full text

Neurological adverse events following CAR T-cell therapy: a real-world analysis by Gajra, Ajeet, Zettler, Marjorie E, Phillips Jr, Eli G, Klink, Andrew J, Jonathan K Kish, Fortier, Stephanie, Mehta, Sonam, Feinberg, Bruce A

“…To characterize real-world neurological adverse events (AEs) associated with chimeric antigen receptor T-cell therapies in patients with refractory/relapsed…”
Get full text

Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting by Mougalian, Sarah S., Copher, Ronda, Kish, Jonathan K., McAllister, Lindsay, Wang, Zhixiao, Broscious, Mary, Garofalo, David, Radtchenko, Janna, Feinberg, Bruce A.

“…Introduction Real‐world data are critical to demonstrate the consistency of evidence and external generalizability of randomized controlled trials (RCTs). This…”
Get full text

Racial and Ethnic Disparities in Cancer Survival by Neighborhood Socioeconomic Status in Surveillance, Epidemiology, and End Results (SEER) Registries by Kish, Jonathan K., Yu, Mandi, Percy-Laurry, Antoinette, Altekruse, Sean F.

“…Introduction Reducing cancer disparities is a major public health objective. Disparities often are discussed in terms of either race and ethnicity or…”
Get full text

Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States by Kish, Jonathan K., Chatterjee, Debanjana, Wan, Yin, Yu, Hsing-Ting, Liassou, Djibril, Feinberg, Bruce A.

“…Introduction Lenvatinib has become the most commonly prescribed first-line (1L) agent for the treatment of radioactive iodine-refractory differentiated thyroid…”
Get full text

Burden of Human Papillomavirus among Haitian Immigrants in Miami, Florida: Community-Based Participatory Research in Action by Kobetz, Erin, Kish, Jonathan K., Campos, Nicole G., Koru-Sengul, Tulay, Bishop, Ian, Lipshultz, Hannah, Barton, Betsy, Barbee, Lindley

“…Background. Haitian immigrant women residing in Little Haiti, a large ethnic enclave in Miami-Dade County, experience the highest cervical cancer incidence…”
Get full text

Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States by Mougalian, Sarah S., Kish, Jonathan K., Zhang, Jingchuan, Liassou, Djibril, Feinberg, Bruce A.

“…Introduction Eribulin was approved in the United States (US) in 2010 for patients with metastatic breast cancer (MBC) who previously received at least two…”
Get full text

Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States by Verstovsek, Srdan, Yu, Jingbo, Kish, Jonathan K., Paranagama, Dilan, Kaufman, Jill, Myerscough, Callan, Grunwald, Michael R., Colucci, Philomena, Mesa, Ruben

“…Myelofibrosis (MF) is a chronic myeloproliferative neoplasm with a prevalence of 4 to 6 per 100,000 people in the USA. Treatment recommendations are…”
Get full text

Understanding total cost of care in advanced non-small cell lung cancer pre- and postapproval of immuno-oncology therapies by Korytowsky, Beata, Radtchenko, Janna, Nwokeji, Esmond D, Tuell, Kenneth W, Kish, Jonathan K, Feinberg, Bruce A

“…This study assesses resource utilization and total direct medical cost among patients in the United States starting systemic antineoplastic therapy (ST) pre-…”
Get full text

Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States by Mougalian, Sarah S., Kish, Jonathan K., Zhang, Jingchuan, Liassou, Djibril, Feinberg, Bruce A.

“…A correction to this paper has been published: https://doi.org/10.1007/s12325-021-01780-0…”
Get full text

Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States by Mougalian, Sarah S., Kish, Jonathan K., Zhang, Jingchuan, Liassou, Djibril, Feinberg, Bruce A.

“…A correction to this paper has been published: https://doi.org/10.1007/s12325-021-01683-0…”
Get full text

Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy by Mougalian, Sarah S, Feinberg, Bruce A, Wang, Edward, Alexis, Karenza, Chatterjee, Debanjana, Knoth, Russell L, Nero, Damion, Miller, Talia, Liassou, Djibril, Kish, Jonathan K

“…To examine the effectiveness of eribulin mesylate for metastatic breast cancer post cyclin-dependent kinase inhibitor (CDKi) 4/6 therapy. US community…”
Get full text

Real-world incidence and cost of pneumonitis post-chemoradiotherapy for Stage III non-small-cell lung cancer by Ryan, Kellie J, Nero, Damion, Feinberg, Bruce A, Lee, Choo Hyung, Pimentel, Rodrigo, Gajra, Ajeet, Kish, Jonathan K, Seal, Brian

“…To estimate the real-world incidence and timing of radiation pneumonitis following chemoradiotherapy for Stage III non-small-cell lung cancer and compare costs…”
Get full text

Preventing heat-related morbidity and mortality: New approaches in a changing climate by O’Neill, Marie S, Carter, Rebecca, Kish, Jonathan K, Gronlund, Carina J, White-Newsome, Jalonne L, Manarolla, Xico, Zanobetti, Antonella, Schwartz, Joel D

“…Abstract Due to global climate change, the world will, on average, experience a higher number of heat waves, and the intensity and length of these heat waves…”
Get full text

Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials by Feinberg, Bruce A, Zettler, Marjorie E, Klink, Andrew J, Lee, Choo H, Gajra, Ajeet, Kish, Jonathan K

“…In clinical trials supporting the regulatory approval of oncology drugs, solid tumor response is assessed using Response Evaluation Criteria in Solid Tumors…”
Get full text

The BEACHES Study: health effects and exposures from non-point source microbial contaminants in subtropical recreational marine waters by Fleisher, Jay M, Fleming, Lora E, Solo-Gabriele, Helena M, Kish, Jonathan K, Sinigalliano, Christopher D, Plano, Lisa, Elmir, Samir M, Wang, John D, Withum, Kelly, Shibata, Tomoyuki, Gidley, Maribeth L, Abdelzaher, Amir, He, Guoqing, Ortega, Cristina, Zhu, Xiaofang, Wright, Mary, Hollenbeck, Julie, Backer, Lorraine C

“…Background Microbial water-quality indicators, in high concentrations in sewage, are used to determine whether water is safe for recreational purposes…”
Get full text

Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework by Roy, Anuja, Kish, Jonathan K, Bloudek, Lisa, Siegel, David S, Jagannath, Sundar, Globe, Denise, Kuriakose, Emil T, Migliaccio-Walle, Kristen

“…Multiple myeloma is a progressive cancer for which there is no cure. Despite treatment, almost all patients eventually experience periods of disease relapse…”
Get full text

Impact of Augmented Intelligence on Utilization of Palliative Care Services in a Real-World Oncology Setting by Gajra, Ajeet, Zettler, Marjorie E, Miller, Kelly A, Frownfelter, John G, Showalter, John, Valley, Amy W, Sharma, Sanya, Sridharan, Shreenath, Kish, Jonathan K, Blau, Sibel

“…For patients with advanced cancer, timely referral to palliative care (PC) services can ensure that end-of-life care aligns with their preferences and goals…”
Get more information